The unprecedented global pandemic caused by coronavirus 2 (SARS-Cov2) drewmedical attention toward patients with co-morbid disorders, who are more exposed to prognostically unfavorable outcomes. A peculiar clinical scenario is represented by oncologic patients, who appear more susceptible to COVID-19 infection, as they may develop more severe symptoms than those observed in individuals with different comorbidity profiles.
On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents
Silvestris, Nicola
Primo
;
2020-01-01
Abstract
The unprecedented global pandemic caused by coronavirus 2 (SARS-Cov2) drewmedical attention toward patients with co-morbid disorders, who are more exposed to prognostically unfavorable outcomes. A peculiar clinical scenario is represented by oncologic patients, who appear more susceptible to COVID-19 infection, as they may develop more severe symptoms than those observed in individuals with different comorbidity profiles.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
fonc-10-01340(3).pdf
accesso aperto
Descrizione: Articolo principale
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
9.15 MB
Formato
Adobe PDF
|
9.15 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
